Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LX6171 High Dose · 1 trial · 1 indication
An adverse event includes any noxious, pathological, or unintended change in anatomical, physiological, or metabolic functions as indicated by physical signs or symptoms occurring in any phase of the clinical study whether or not associated with the study medication and whether or not considered related to study medication.
Subjects were considered compliant if they had taken \>70% of possible doses of the study drug.
| Arm | Type | Description |
|---|---|---|
| High Dose | EXPERIMENTAL | - |
| Low Dose | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| LX6171 High Dose | DRUG | A high dose of LX6171, using an oral suspension; daily oral intake for 28 days in the morning at approximately the same time. |
| LX6171 Low Dose | DRUG | A low dose of LX6171, using an oral suspension; daily oral intake for 28 days in the morning at approximately the same time. |
| Placebo | DRUG | Matching placebo dosing with daily oral intake for 28 days in the morning at approximately the same time. |
Inclusion Criteria: * Males and females aged 60-80 years old. * Complaints of memory loss in everyday life * Non-smokers or very light smokers (no more than 10 cigarettes/day) * Negative urine screen for drugs of abuse * Ability to provide written informed consent Exclusion Criteria: * History or...
LX6171 High Dose is an investigational small molecule being developed for age-related memory disorders. It was studied in elderly volunteers with age-associated memory impairment. The drug is in Phase 2 clinical development and is not approved by the FDA.
LX6171 High Dose is being developed by Lexicon Pharmaceuticals, Inc., a biopharmaceutical company traded on the Nasdaq under the ticker LXRX. The company conducted a Phase 2 clinical trial of the drug in elderly volunteers with age-associated memory impairment.
LX6171 High Dose is in Phase 2 clinical development. A Phase 2 study of the drug has been completed. The drug is investigational and has not been approved by the FDA for any use.
LX6171 High Dose has one completed clinical trial, identified as NCT00691808. This Phase 2 study, titled 'Study of LX6171 in Elderly Volunteers With Age Associated Memory Impairment,' enrolled 103 participants in the Netherlands. The trial was randomized, double-blind, and placebo-controlled.
LX6171 High Dose is a specific dosage form of the investigational drug LX6171. The completed Phase 2 trial NCT00691808 studied LX6171 in elderly volunteers with age-associated memory impairment, and the high dose refers to one of the dosage levels evaluated in that study.